Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)

NCT00577824 on ClinicalTrials.gov · last registry update 2015-04-09

A small phase 3 — 181 participants, against a typical 424. The sponsor logged completion for November 2008. Primary outcome, as filed: Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: AstraZeneca
Sponsor type: Industry
Enrollment: 181
Started: 2008-01
Primary completion: 2008-11 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.